Press Release: Sanofi completes acquisition of Vicebio

Core Insights - Sanofi has successfully completed the acquisition of Vicebio Ltd, enhancing its capabilities in vaccine design and development, particularly for respiratory viruses [1][2] Group 1: Acquisition Details - The acquisition includes an early-stage combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) [1] - This addition allows Sanofi to diversify its vaccine pipeline by incorporating a non-mRNA vaccine option, thereby increasing choices for physicians and patients [2] Group 2: Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [3] - The company aims to leverage its deep understanding of the immune system to develop treatments that can benefit millions globally [3]